Effectiveness of triple therapy with dapagliflozin add-on to dual therapy over 52 weeks in patients with uncontrolled type 2 diabetes mellitus in a centre of high complexity, Cali-Colombia
ABSTRACT Objectives: To evaluate the effectiveness of adding dapagliflozin as an intensification strategy for the treatment of patients with uncontrolled type 2 diabetes mellitus (T2DM). Materials and methods: A historical cohort study was conducted in 123 adult patients over 18 years old who were...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Brazilian Society of Endocrinology and Metabolism
2021-01-01
|
| Series: | Archives of Endocrinology and Metabolism |
| Subjects: | |
| Online Access: | http://www.scielo.br/scielo.php?script=sci_arttext&pid=S2359-39972021000100049&tlng=en |
| _version_ | 1818719908825923584 |
|---|---|
| author | Vanessa Bedoya Joaqui Nathalia Buitrago Gómez Reinaldo Carvajal Ortiz Luis Miguel Osorio Toro Jenny Patricia Muñoz Lombo Carlos Alberto Salgado Cifuentes Mónica Andrea Morales García Alín Abreu Lomba |
| author_facet | Vanessa Bedoya Joaqui Nathalia Buitrago Gómez Reinaldo Carvajal Ortiz Luis Miguel Osorio Toro Jenny Patricia Muñoz Lombo Carlos Alberto Salgado Cifuentes Mónica Andrea Morales García Alín Abreu Lomba |
| author_sort | Vanessa Bedoya Joaqui |
| collection | DOAJ |
| description | ABSTRACT Objectives: To evaluate the effectiveness of adding dapagliflozin as an intensification strategy for the treatment of patients with uncontrolled type 2 diabetes mellitus (T2DM). Materials and methods: A historical cohort study was conducted in 123 adult patients over 18 years old who were diagnosed with uncontrolled T2DM, who received dapagliflozin add-on to their dual base treatment: metformin plus glibenclamide (n = 32), metformin plus saxagliptin (n = 29), metformin plus exenatide (n = 28), or metformin plus insulin (n = 34). The endpoints were evaluated using analysis of variance. Results: All the patients completed a 52-week follow-up. Overall, 52.85% of patients were female, the Hispanic population represented the largest proportion of patients in all groups (60.98%), and the mean ± SD patient age and body weight were 55.05 ± 7.58 years and 83.55 ± 9.65 kg, respectively. The mean ± SD duration of T2DM, glycated hemoglobin (HbA1c), and fasting plasma glucose (FPG) were 5.93 ± 2.98 years, 8.1 ± 0.53%, and 166.03 ± 26.80 mg/dL, respectively. The grand mean changes of HbA1c, FPG, body weight and blood pressure showed a decreasing trend during the study period and it was statistically significant in all groups (p-value = <0.001). The proportion of patients achieving HbA1c target (<7%) was highest in the group that used a dapagliflozin add-on to metformin plus saxagliptin. Conclusion: The addition of dapagliflozin as an alternative for intensification of dual therapy consistently improved, not only FPG and HbA1c, but also body weight and blood pressure, with statistically significant results. |
| first_indexed | 2024-12-17T20:14:25Z |
| format | Article |
| id | doaj.art-67d2eb5dda5543b98015a9cf00e75f40 |
| institution | Directory Open Access Journal |
| issn | 2359-4292 |
| language | English |
| last_indexed | 2024-12-17T20:14:25Z |
| publishDate | 2021-01-01 |
| publisher | Brazilian Society of Endocrinology and Metabolism |
| record_format | Article |
| series | Archives of Endocrinology and Metabolism |
| spelling | doaj.art-67d2eb5dda5543b98015a9cf00e75f402022-12-21T21:34:08ZengBrazilian Society of Endocrinology and MetabolismArchives of Endocrinology and Metabolism2359-42922021-01-01651495910.20945/2359-3997000000319Effectiveness of triple therapy with dapagliflozin add-on to dual therapy over 52 weeks in patients with uncontrolled type 2 diabetes mellitus in a centre of high complexity, Cali-ColombiaVanessa Bedoya Joaquihttps://orcid.org/0000-0002-4933-9107Nathalia Buitrago Gómezhttps://orcid.org/0000-0001-7466-9645Reinaldo Carvajal Ortizhttps://orcid.org/0000-0002-5312-8281Luis Miguel Osorio Torohttps://orcid.org/0000-0002-1971-6354Jenny Patricia Muñoz Lombohttps://orcid.org/0000-0002-9281-2844Carlos Alberto Salgado Cifuenteshttps://orcid.org/0000-0003-3193-7739Mónica Andrea Morales Garcíahttps://orcid.org/0000-0002-3202-5734Alín Abreu Lombahttps://orcid.org/0000-0002-7377-4969ABSTRACT Objectives: To evaluate the effectiveness of adding dapagliflozin as an intensification strategy for the treatment of patients with uncontrolled type 2 diabetes mellitus (T2DM). Materials and methods: A historical cohort study was conducted in 123 adult patients over 18 years old who were diagnosed with uncontrolled T2DM, who received dapagliflozin add-on to their dual base treatment: metformin plus glibenclamide (n = 32), metformin plus saxagliptin (n = 29), metformin plus exenatide (n = 28), or metformin plus insulin (n = 34). The endpoints were evaluated using analysis of variance. Results: All the patients completed a 52-week follow-up. Overall, 52.85% of patients were female, the Hispanic population represented the largest proportion of patients in all groups (60.98%), and the mean ± SD patient age and body weight were 55.05 ± 7.58 years and 83.55 ± 9.65 kg, respectively. The mean ± SD duration of T2DM, glycated hemoglobin (HbA1c), and fasting plasma glucose (FPG) were 5.93 ± 2.98 years, 8.1 ± 0.53%, and 166.03 ± 26.80 mg/dL, respectively. The grand mean changes of HbA1c, FPG, body weight and blood pressure showed a decreasing trend during the study period and it was statistically significant in all groups (p-value = <0.001). The proportion of patients achieving HbA1c target (<7%) was highest in the group that used a dapagliflozin add-on to metformin plus saxagliptin. Conclusion: The addition of dapagliflozin as an alternative for intensification of dual therapy consistently improved, not only FPG and HbA1c, but also body weight and blood pressure, with statistically significant results.http://www.scielo.br/scielo.php?script=sci_arttext&pid=S2359-39972021000100049&tlng=enDiabetes mellituscombined modality therapyhypoglycemic agents |
| spellingShingle | Vanessa Bedoya Joaqui Nathalia Buitrago Gómez Reinaldo Carvajal Ortiz Luis Miguel Osorio Toro Jenny Patricia Muñoz Lombo Carlos Alberto Salgado Cifuentes Mónica Andrea Morales García Alín Abreu Lomba Effectiveness of triple therapy with dapagliflozin add-on to dual therapy over 52 weeks in patients with uncontrolled type 2 diabetes mellitus in a centre of high complexity, Cali-Colombia Archives of Endocrinology and Metabolism Diabetes mellitus combined modality therapy hypoglycemic agents |
| title | Effectiveness of triple therapy with dapagliflozin add-on to dual therapy over 52 weeks in patients with uncontrolled type 2 diabetes mellitus in a centre of high complexity, Cali-Colombia |
| title_full | Effectiveness of triple therapy with dapagliflozin add-on to dual therapy over 52 weeks in patients with uncontrolled type 2 diabetes mellitus in a centre of high complexity, Cali-Colombia |
| title_fullStr | Effectiveness of triple therapy with dapagliflozin add-on to dual therapy over 52 weeks in patients with uncontrolled type 2 diabetes mellitus in a centre of high complexity, Cali-Colombia |
| title_full_unstemmed | Effectiveness of triple therapy with dapagliflozin add-on to dual therapy over 52 weeks in patients with uncontrolled type 2 diabetes mellitus in a centre of high complexity, Cali-Colombia |
| title_short | Effectiveness of triple therapy with dapagliflozin add-on to dual therapy over 52 weeks in patients with uncontrolled type 2 diabetes mellitus in a centre of high complexity, Cali-Colombia |
| title_sort | effectiveness of triple therapy with dapagliflozin add on to dual therapy over 52 weeks in patients with uncontrolled type 2 diabetes mellitus in a centre of high complexity cali colombia |
| topic | Diabetes mellitus combined modality therapy hypoglycemic agents |
| url | http://www.scielo.br/scielo.php?script=sci_arttext&pid=S2359-39972021000100049&tlng=en |
| work_keys_str_mv | AT vanessabedoyajoaqui effectivenessoftripletherapywithdapagliflozinaddontodualtherapyover52weeksinpatientswithuncontrolledtype2diabetesmellitusinacentreofhighcomplexitycalicolombia AT nathaliabuitragogomez effectivenessoftripletherapywithdapagliflozinaddontodualtherapyover52weeksinpatientswithuncontrolledtype2diabetesmellitusinacentreofhighcomplexitycalicolombia AT reinaldocarvajalortiz effectivenessoftripletherapywithdapagliflozinaddontodualtherapyover52weeksinpatientswithuncontrolledtype2diabetesmellitusinacentreofhighcomplexitycalicolombia AT luismiguelosoriotoro effectivenessoftripletherapywithdapagliflozinaddontodualtherapyover52weeksinpatientswithuncontrolledtype2diabetesmellitusinacentreofhighcomplexitycalicolombia AT jennypatriciamunozlombo effectivenessoftripletherapywithdapagliflozinaddontodualtherapyover52weeksinpatientswithuncontrolledtype2diabetesmellitusinacentreofhighcomplexitycalicolombia AT carlosalbertosalgadocifuentes effectivenessoftripletherapywithdapagliflozinaddontodualtherapyover52weeksinpatientswithuncontrolledtype2diabetesmellitusinacentreofhighcomplexitycalicolombia AT monicaandreamoralesgarcia effectivenessoftripletherapywithdapagliflozinaddontodualtherapyover52weeksinpatientswithuncontrolledtype2diabetesmellitusinacentreofhighcomplexitycalicolombia AT alinabreulomba effectivenessoftripletherapywithdapagliflozinaddontodualtherapyover52weeksinpatientswithuncontrolledtype2diabetesmellitusinacentreofhighcomplexitycalicolombia |